A peptide that binds copper
GHK contains three amino acids: glycine, histidine and lysine. GHK-Cu is the copper-bound form. GHK occurs naturally in human fluids, including blood plasma, but that does not establish the effects or safety of adding more.
Names matter in this literature. Free GHK, GHK-Cu and chemically modified forms are different materials. A study that tested one cannot automatically support claims about another. The ingredient name copper tripeptide-1 often appears in the cosmetic context.
Collagen and tissue maintenance
A 2015 review of skin biology describes effects on cultured fibroblasts, cells that make the supporting material around them. The findings include collagen production and changes in processes that break down and replace that material.
That balance is important to the research question. More collagen in a dish is a measurable result, but it does not by itself establish firmer skin, fewer wrinkles or better wound healing in a person. Tissue maintenance involves the arrangement and function of the material as well as how much is made.
Reviews bring several kinds of experiments together. Their broad language needs to be interpreted alongside the original setting: cells, animals, removed skin or living participants. Those settings answer different questions.
What topical studies can tell us
A 2025 review of topical GHK describes promising laboratory findings alongside a limited clinical literature. Some often-repeated cosmetic results come through summaries of older work rather than accessible, fully reported journal trials.
Delivery through the skin is another issue. In a laboratory study using removed human skin, researchers measured copper passing into and through skin layers. Measuring copper is not the same as demonstrating that intact GHK-Cu reached a particular target in a living person.
The formulation also matters. A cream contains other ingredients, and skin exposure differs from an injection. A topical outcome cannot establish the safety of circulating GHK-Cu throughout the body.
Hair findings need a separate label
A 2016 trial involving men with hair loss tested a combination of free GHK and another ingredient. It did not test GHK-Cu alone. The results therefore do not establish GHK-Cu as a hair-loss treatment.
This distinction is easy to lose when several compounds share part of a name. A useful account keeps the tested formulation beside the result, rather than turning a combination finding into a claim about every copper peptide.
Safety depends on the route
People in skincare communities report smoother-feeling skin, but also stinging, dryness and redness. These reports are anecdotal, not clinical evidence. They cannot provide a reliable rate of benefit or irritation, and they do not describe the risk of an injection.
The FDA's safety-risk page, current as of April 22, 2026, lists injectable GHK-Cu as nominated but withdrawn. It retains concerns about immune reactions, peptide aggregation and impurities, with limited human safety data. Withdrawal is not approval or clearance.
Non-injectable GHK-Cu has a separate entry in the 503A list updated May 14, 2026. Its Category 1 listing describes evaluation under an interim policy, not approval of a medicine. It cannot be used to describe the injectable form as approved.
Where GHK-Cu fits among the topics
The strongest reason to separate GHK-Cu from BPC-157 is the difference in the questions being studied. Skin appearance, collagen production and tendon strength are not one shared outcome. Neither compound's literature establishes the performance of a blend.
The GLOW page describes why adding GHK-Cu to BPC-157 and TB-500 creates a new question. The comparison places topical and injury studies alongside each other without ranking them as treatments.